The phase 3 MATTERHORN study presented at the 2025 ASCO Annual Meeting and published in the Journal of Clinical Oncology evaluated event-free survival with the combination of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in patients with resectable gastric/gastroesophageal junction cancer.
